RxDoctor Payments Data

Christopher Koman, MD

Family Medicine · Pittsburgh, PANPI 1437149002

Payments from drug & device makers

$1,033in general payments, 2019–2025

Across 28 payments — averaging $36.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$511
  • Novo Nordisk$198
  • Pfizer$81
  • Exact Sciences$50
  • Tosoh Bioscience, Inc.$47
  • Merck$45
  • plus $101 from 4 others

What the payments were for

  • Speaking & faculty fees$51149%
  • Food & beverage$47546%
  • Gifts$475%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK1$511
Novo Nordisk11$198
Pfizer5$81
Exact Sciences3$50
Tosoh Bioscience, Inc.1$47
Merck2$45
Medicomp Inc2$35
Boston Scientific1$26
Abbott1$21
AbbVie1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,033 in reported general payments places this provider in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$216,530
Medicare patients
389
Services billed
3,728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban169$113,135
OzempicSemaglutide76$73,083
XareltoRivaroxaban94$54,299
JardianceEmpagliflozin39$26,276
TrulicityDulaglutide49$26,257
ArexvyRsvpref3 Antigen/As01e/Pf67$19,741
AbrysvoRsv Vacc, Pref A And Pref B/Pf48$15,259
TradjentaLinagliptin34$15,252
MyrbetriqMirabegron32$13,759
CreonLipase/Protease/Amylase12$11,937
JanuviaSitagliptin Phosphate17$11,516
EntrestoSacubitril/Valsartan22$9,410
ShingrixVaricella-Zoster Ge/As01b/Pf46$9,375
Enoxaparin Sodium19$8,335
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,864

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$81$128,394217 claims
Novo NordiskOzempic$198$73,08376 claims
GSKArexvy, Shingrix, Trelegy Ellipta$511$36,980125 claims
AbbVieCreon, Synthroid, Lumigan$18$20,00779 claims
MerckJanuvia$45$11,51617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →